Binh Dinh Pharmaceutical & Medical Equipment JSC
HHOSE:DBD46,750.00
VND
+650.00
(+1.41%)
ISIN
VN000000DBD0
Return %
Stock
S&P 500
1Y
-12.45
14.20
3Y
-0.79
81.12
5Y
60.95
68.34
Capital Structure
VND
•
in mil. unless spec.Working Capital
VND
•
in mil. unless spec.Growth Rates
VND
•
in mil. unless spec.Quarterly Revenue
VND
•
in mil. unless spec.Quarterly Earnings Per Share
VND
•
in mil. unless spec.Quarterly Dividends Per Share
VND
•
in mil. unless spec.Company Description
- CEO
- Thanh Huong Thi Pham
- Full Time Employees
- 1,375
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Quy Nhon Vietnam
- IPO Date
- Jun 11, 2018
- Website
- bidiphar.com
- Similar Companies
- Business
- Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company (Bidiphar) is a Vietnam-based pharmaceutical and healthcare company engaged in the research, development, manufacturing, and commercialization of pharmaceutical preparations, specialized therapeutics, and medical equipment. The company's core product portfolio encompasses specialized oncology and antineoplastic pharmaceuticals; sterile small-volume and large-volume injectables; hemodialysis concentrates and peritoneal dialysis solutions; systemic antibiotics, cephalosporins, and other anti-infective formulations; cardiovascular, metabolic, and central nervous system therapeutics; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; vitamins, mineral dietary supplements, and therapeutic nutrition products; standardized herbal medicines and bioactive phytotherapeutic compounds; and specialized medical machinery and healthcare apparatus, including medical solid waste incinerators, automated herbal extraction and brewing systems, and water distillation equipment. Bidiphar supplies national and provincial healthcare institutions through the hospital-based ethical drug channel (ETC) as well as commercial retail pharmacy networks across Vietnam through the over-the-counter (OTC) channel, while exporting finished formulations to international markets across Southeast and Central Asia, including Cambodia, Laos, Myanmar, and Mongolia. In recent operational and strategic developments, Bidiphar has advanced a multi-facility expansion program focused on European Union Good Manufacturing Practice (EU-GMP) compliance to qualify for high-tier institutional public hospital tenders. The company inaugurated a dedicated oncology pharmaceutical manufacturing facility in the Nhon Hoi Economic Zone and commenced construction of an 840 billion VND EU-GMP standard sterile small-volume injectable manufacturing plant. Additionally, the company initiated the development of an 870 billion VND non-betalactam oral solid dosage (OSD) manufacturing facility and approved private placement equity offerings to secure international strategic pharmaceutical partners for advanced technology transfer and export market expansion. Founded in 1979, converted to a joint-stock enterprise in 2014, and listed on the Ho Chi Minh Stock Exchange under the ticker symbol DBD, Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company is headquartered in Quy Nhon, Binh Dinh Province, Vietnam.